2.1
Spesolimab (Spevigo, Boehringer Ingelheim) is indicated 'for the treatment of flares in adult patients with generalised pustular psoriasis'.
2 Information about spesolimab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for spesolimab.
Price
2.3
The list price for spesolimab is £15,000 for 2 450‑mg vials (excluding VAT; BNF, accessed December 2024).
2.4
The company has a commercial arrangement. This makes spesolimab available to the NHS with a discount. The size of the discount is commercial in confidence.